MedPath

Efficacy and Safety of Basal-Bolus Insulin Therapy with SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus Hospitalized for Hyperglycemia

Not Applicable
Recruiting
Conditions
Type 2 diabetes
Registration Number
JPRN-UMIN000053224
Lead Sponsor
Ichinomiynishi Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
36
Inclusion Criteria

Not provided

Exclusion Criteria

1) Type 1 diabetes mellitus 2) Frequent insulin injections 3) Pregnancy 4) On SGLT2 inhibitors (washout for at least 1 week is acceptable) 5) DPP4 inhibitor in once-weekly formulation 6) Once-weekly GLP-1RA 7) Undergoing chemotherapy 8) DKA or history of DKA 9) Hyperglycemic coma 10)High-dose steroids (>10 mg PSL equivalent)

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath